Rappel de ARCHITECT "I" SYSTEM - ANTI-HCV

Selon Health Canada (via FOI), ce/cet/cette rappel concerne un dispositif en/au/aux/à Canada qui a été fabriqué par ABBOTT LABORATORIES LIMITED. DIAGNOSTIC DIVISION.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    30387
  • Classe de risque de l'événement
    III
  • Date de mise en oeuvre de l'événement
    2010-03-19
  • Pays de l'événement
  • Source de l'événement
    HC
  • Notes / Alertes
    Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
  • Notes supplémentaires dans les données
  • Cause
    The following may occur near the end of the volume of the architect anti-hcv reagent: - abbott positive control values shift down and/or out of range low -non-abbott positive control values shift down and/or out of range low and/or -decreased patient s/co values potentially leading to false non-reactive results.

Device

  • Modèle / numéro de série
    Model Catalog: 6C37-25 (Lot serial: ALL LOTS); Model Catalog: 6C37-20 (Lot serial: ALL LOTS); Model Catalog: 6C37-30 (Lot serial: ALL LOTS)
  • Description du dispositif
    ARCHITECT ANTI-HCV REAGENTS
  • Manufacturer

Manufacturer

  • Adresse du fabricant
    MISSISSAUGA
  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    HC